GLP-1 Investing Hub 2026: Eli Lilly, Novo Nordisk, Oral Pills, Compounding & Supply-Chain Stocks
By OneDayAdvisor Editorial Team | Published: October 14, 2026 | Last updated: October 14, 2026 | Reading time: about 14 minutes
- 1. Market snapshot: the numbers that matter
- 2. Eli Lilly vs Novo Nordisk scorecard
- 3. Oral pills: Wegovy pill vs Foundayo
- 4. Pricing, Medicare and access
- 5. Compounded GLP-1s and the crackdown
- 6. Suppliers: the picks-and-shovels layer
- 7. The next wave: pipeline and challengers
- 8. Risk map
- 9. Catalyst calendar
- 10. Ways to get exposure
- 11. Investor checklist
- 12. Using AI to research GLP-1 stocks
- 13. FAQ
- 14. Sources and change log
1. Market snapshot: the numbers that matter
Direct answer: demand for GLP-1 medicines is still compounding, but the business model is shifting from high list prices to high volume at lower net prices. Lilly is capturing most of the growth; Novo is defending with the Wegovy pill and higher-dose Wegovy.
| Metric (Q2 2026) | Eli Lilly (LLY) | Novo Nordisk (NVO) |
|---|---|---|
| Top line | Revenue $23.0B, +48% [1] | Adjusted sales DKK 78.5B, +7% at constant exchange rates [5] |
| Profit | Non-GAAP EPS $8.38, +33%, after $3.03 of acquired IPR&D charges [1] | Adjusted operating profit DKK 33.4B, +11% CER; operating margin 42.5% [5] [4] |
| Gross margin | 85.8% reported [1] | 78.2% [5] |
| Flagship GLP-1 sales | Mounjaro $9.9B (+91%); Zepbound $4.9B [1] [3] | Wegovy pill about DKK 3.2B (roughly $0.5B) in its first full quarters; more than 5 million cumulative US prescriptions [3] [4] |
| 2026 guidance | Revenue $85-87B; non-GAAP EPS $35.50-36.50 [1] | Adjusted sales and operating profit growth of 0% to -6% CER, raised for the second time; non-adjusted midpoint implies about +5% sales, +12% operating profit [5] |
| Pricing signal | Realized price on Zepbound and Mounjaro fell; management cited about 9% underlying price compression before rebate revisions [2] | Lower realized prices and US pricing pressure cited [5] |
| One-offs | Large acquired IPR&D charge in the quarter [1] | DKK 6.3B non-cash impairments on pipeline assets, including monlunabant (DKK 4.0B) [4] |
Figures are company-reported or taken from the linked summaries; Novo reports in Danish kroner and Lilly in US dollars, so compare growth rates and margins rather than absolute amounts.
Mounjaro and Zepbound together were about $14.9 billion of Lilly's $23.0 billion quarterly revenue, roughly 65%. That concentration is the single biggest reason Lilly's results swing with GLP-1 pricing and policy news. [1]
2. Eli Lilly vs Novo Nordisk scorecard
Direct answer: on Q2 2026 results Lilly leads on growth, margin and next-generation pipeline momentum, while Novo leads on oral-pill uptake and is rebuilding from a weaker 2025. Neither result tells you which stock is cheaper today; that needs current prices and estimates.
.png "Best Weight Loss Peptides")
| Factor | Eli Lilly | Novo Nordisk | Edge (on the evidence above) |
|---|---|---|---|
| Growth | Revenue +48%; international +80% (113% volume growth), China boosted by reimbursement listing [2] [1] | Adjusted sales +7% CER; reported +3% against a one-off 2025 comparison [4] | Lilly |
| Oral launch | Foundayo approved Apr 1, 2026; slower start but no food or water restrictions [7] [6] | Wegovy pill launched Jan 2026; one of the fastest launches in history [6] | Novo |
| Next-gen injectables | Retatrutide Phase 3 package complete; FDA filing planned Q1 2027 [1] | Wegovy HD (7.2 mg) launched in US in April; CagriSema filing was planned for Q1 2026 (verify current status) [4] [21] | Lilly |
| Capacity | Added $4.5B for Indiana manufacturing [3] | Large capital programme; sales and distribution costs +13% to support the pill launch [5] | Even |
| Guidance tone | Raised full-year revenue guidance to $85-87B [1] | Raised twice in 2026, but still points to flat-to-lower adjusted growth [5] | Lilly |
| Key risk | Product concentration and price compression | Share loss in injectables, US pricing, patent expiries abroad [5] | Both exposed |
“Edge” compares operating momentum only. It is not a valuation call or a recommendation.
For a longer head-to-head with trial data, read our Eli Lilly vs Novo Nordisk GLP-1 showdown, and for sector context see the market sector rotation analysis and the Stocks Hub.
3. Oral pills: Wegovy pill vs Foundayo
Direct answer: the Wegovy pill (oral semaglutide) has the early lead and higher reported trial weight loss, while Foundayo (orforglipron) is easier to take and cheaper at the entry dose in some markets. Both start at $149 per month self-pay in the US.
| Attribute | Wegovy pill (Novo Nordisk) | Foundayo (Eli Lilly) |
|---|---|---|
| Molecule | Oral semaglutide (peptide) | Orforglipron (small-molecule GLP-1 agonist) |
| US status | Approved Dec 2025; launched Jan 2026 [9] | Approved Apr 1, 2026; shipping from Apr 6 [7] |
| How to take | First thing in the morning on an empty stomach, 30 minutes before food or drink [6] | Any time of day, no food or water restrictions [6] |
| Trial weight loss | Up to 16.6% mean (OASIS 4) [4] | 12.4% at 72 weeks (ATTAIN-1) [6] |
| US cash price | $149-$299 per month by dose [8] | $149-$349 per month by dose [8] |
| Insured | As low as $25 per month with commercial coverage [9] | As low as $25 with the savings card [6] |
| Traction | More than 5M cumulative US prescriptions; over 265,000 weekly (week to Jul 17) [4] | 1,390 prescriptions in debut week (IQVIA) [7] |
| Outside the US | UAE (June) and UK (July) launches; EMA approval in July [4] | UK launch Aug 25 after MHRA approval; EU under review [8] |
The two pills have not been tested head to head; trial populations and designs differ, so weight-loss figures are not directly comparable.
What the pill race means for investors
- Market expansion: Lilly's CEO has said almost all Wegovy pill starters were new to GLP-1s, which supports the view that pills widen the patient pool rather than only cannibalize injections. [6]
- Margin and price: pills launched at $149 entry prices, lower than injectable cash prices, so revenue per patient is likely to be lower even if patient counts are higher.
- Supply-chain mix: a growing oral share reduces injection-device and glass demand per patient, which matters for the component makers in section 6.
- Read-through to the weekly scripts: IQVIA prescription data is the most-watched near-term indicator for both pills; treat single-week prints as noisy.
Related reading: our Wegovy pill vs Foundayo pill comparison.
4. Pricing, Medicare and access
Direct answer: US GLP-1 prices are falling through cash-pay programs, government deals and a new Medicare bridge. Lilly said self-pay accounted for 45% of Zepbound prescriptions and 55% of new prescriptions in Q2 2026, which shows how quickly the channel mix has changed. [2]
| Channel | What is available (as reported) | Investor implication |
|---|---|---|
| Self-pay (Lilly) | Zepbound vials from $299 (2.5 mg), $399 (5 mg), $449 (7.5 mg and above); Foundayo from $149 [9] | Higher volume, lower realized price |
| Self-pay (Novo) | Wegovy injection $349 cash for doses 0.25-2.4 mg; Wegovy pill from $149 [9] | Defends share but compresses net price |
| Medicare GLP-1 Bridge | $50 monthly copay for eligible Part D enrollees from Jul 1, 2026, scheduled to run to Dec 31, 2027; copays sit outside the standard Part D cap [10] | New volume pool; time-limited demonstration |
| Government price deal | Medicare price reported at $245 per month; TrumpRx direct-to-consumer pricing around $346 average for Zepbound and about $150 for initial oral doses [11] | Anchors future net-price expectations |
| Commercial insurance | Savings programmes as low as $25 per month for eligible patients [9] | Coverage decisions by employers remain a swing factor |
Prices and programme terms change often; confirm on each manufacturer's site before relying on them.
Negotiated Medicare prices for semaglutide are also scheduled to start in 2027, so policy risk does not end with the bridge. Eligibility is limited to patients with obesity plus related conditions rather than weight loss alone. [11]
5. Compounded GLP-1s and the crackdown
Direct answer: the compounding channel is shrinking under FDA and litigation pressure, which is a tailwind for branded volume and a headwind for telehealth businesses that relied on it. Compounded drugs are not FDA-approved, and Novo estimated about 1 million people used a compounded GLP-1 last year. [14]
| Date | Event | Why it matters |
|---|---|---|
| Late 2024 | FDA declared the tirzepatide shortage over [12] | Removed the main legal basis for mass compounding |
| Sep 16, 2025 | FDA sent more than 55 warning letters to online sellers of compounded GLP-1s [12] | Enforcement escalated from guidance to action |
| Feb 5-7, 2026 | Hims & Hers announced a $49 compounded semaglutide pill, then withdrew it within days [13] | Showed regulatory limits in real time |
| Feb 9, 2026 | Novo Nordisk sued Hims & Hers for patent infringement [12] | Branded makers began litigating against large telehealth sellers |
| Mar 3, 2026 | FDA sent warning letters to 30 telehealth companies over misleading claims [14] | Marketing claims now a direct enforcement target |
| Early Mar 2026 | Hims & Hers and Novo announced a partnership: branded Ozempic and Wegovy offered, most compounded advertising stopped; Novo dismissed its suit but kept the right to refile [12] | Shift from confrontation to channel partnership |
Reading the table as an investor: telehealth platforms that depended on compounded margins face business-model risk, while Lilly and Novo gain if displaced patients move to branded cash-pay products. Patients should not switch or stop any prescribed therapy without a licensed clinician.
6. Suppliers: the picks-and-shovels layer
Direct answer: an injectable GLP-1 needs a peptide ingredient, sterile fill-finish, glass or plastic primary packaging, elastomer seals and a delivery device, each made by specialists. Peptide synthesis is slow and multi-step, which is why capacity there is often described as the first physical bottleneck. [16] [15]
| Layer | Role in a GLP-1 product | Companies commonly cited | What to verify |
|---|---|---|---|
| Peptide ingredient (CDMO) | Solid-phase or liquid-phase peptide synthesis of the active ingredient | Bachem, PolyPeptide; India-based Neuland and Sai Life; CPC Scientific (private) [16] [15] [17] | Share of revenue from GLP-1 programmes; customer concentration; capacity ramp timing |
| Sterile fill-finish | Filling cartridges, pens and vials | In-house at Lilly and Novo; contract sites including those Novo Holdings gained through Catalent | Whether capacity is captive or open to third parties |
| Glass and primary packaging | Cartridges, syringes, vials | Stevanato, SCHOTT Pharma, Gerresheimer [17] | Order books tied to named programmes; destocking cycles |
| Elastomer components | Plungers and seals in injection devices | West Pharmaceutical Services [16] | GLP-1 share of revenue; sensitivity to oral shift |
| Devices and needles | Pens, autoinjectors, pen needles | BD, and the drugmakers' own device teams | Whether the device is proprietary to Lilly or Novo |
Classification is editorial and for research orientation only; it is not an endorsement. GLP-1 revenue exposure is frequently undisclosed, so confirm in each company's filings.
Three supplier-specific risks
- Oral substitution: pills need no glass, seals or pens, so a faster shift to oral lowers component intensity per patient.
- Vertical integration: Lilly is committing billions to its own plants, which can reduce reliance on outside capacity over time. [3]
- Overbuild: if many CDMOs add peptide capacity at once, pricing power can fade. Chinese and Indian peptide CDMOs are expanding aggressively. [15]
7. The next wave: pipeline and challengers
Direct answer: the next competitive phase is about monthly dosing, amylin combinations, triple agonists and oral small molecules. Several big companies are now in late-stage trials, but approvals are mostly 2027 or later, so these are scenario inputs, not near-term earnings drivers.
| Company and asset | Type | Stage (as reported) | Why it matters |
|---|---|---|---|
| Lilly: retatrutide | GLP-1, GIP and glucagon triple agonist | Phase 3 package complete for obesity, sleep apnea and knee osteoarthritis pain; FDA filing planned Q1 2027 [1] | Could raise the efficacy bar in obesity |
| Novo: CagriSema | Amylin plus GLP-1 combination | Filing planned for Q1 2026; confirm current regulatory status [21] | Novo's most advanced next-gen injectable |
| Pfizer: PF-08653944 (from Metsera) | Ultra-long-acting GLP-1, monthly potential | Phase 3; about 10 Phase 3 trials planned in 2026; Metsera deal reached roughly $10B after a bidding war [18] | Pfizer's re-entry; monthly dosing is a differentiator |
| Amgen: MariTide | Antibody-peptide conjugate (GIPR antagonist plus GLP-1) | Broad Phase 3 (MARITIME) programme in obesity and related conditions [20] [19] | Monthly or less frequent dosing potential |
| Roche: CT-388 and petrelintide | GLP-1/GIP candidate; amylin analogue (from Zealand deal worth up to $5.3B) | CT-388 advanced to late-stage trials [21] | Amylin could pair with incretins |
| Viking: VK2735 | Dual agonist (injectable and oral candidates) | Clinical-stage; next update not expected before early 2027 per Zacks [19] | Takeover and binary-event risk |
Structure Therapeutics and others are also advancing oral candidates; stage and timing details change with each readout.
8. Risk map
Direct answer: the largest risks are not demand but price, policy and concentration. A risk map is more useful than a single bull or bear case.
| Risk | How it shows up | Most exposed | Signal to watch |
|---|---|---|---|
| Price compression | Cash-pay cuts, government deals, rebate changes | Lilly (Zepbound and Mounjaro about 65% of Q2 revenue), Novo | Realized price per script; gross margin trend |
| Policy | Medicare Bridge ends Dec 31, 2027; negotiated semaglutide pricing in 2027 | Both | CMS announcements; TrumpRx terms |
| Competition | Pfizer, Amgen, Roche and others entering; share shifts between Lilly and Novo | Both | Phase 3 readouts; IQVIA script share |
| Compounding and counterfeit | Unapproved copies and misleading marketing | Novo especially; telehealth platforms | FDA warning letters; patent litigation |
| Safety and litigation | Class-wide label updates or new side-effect signals | All GLP-1 makers | FDA safety communications; trial discontinuations |
| Oral shift | Lower revenue per patient; less injection-component demand | Component suppliers | Pill share of new prescriptions |
| International patents | Semaglutide generics outside the US | Novo | Novo commentary on International Operations [5] |
| Expectations | Strong results already reflected in valuation | Both | Forward multiples versus growth |
9. Catalyst calendar
Direct answer: the next hard data points are Q3 earnings in late October and early November, followed by the retatrutide filing in Q1 2027. Dates marked “estimated” are from data providers and should be confirmed on company investor-relations pages.
| Event | Timing | What to look for |
|---|---|---|
| Lilly Q3 2026 results | Estimated Oct 29 to Nov 2, 2026 (unconfirmed) [22] | Mounjaro and Zepbound growth, Foundayo revenue, price versus volume, guidance |
| Novo Q3 2026 results | Estimated about Nov 4, 2026 (unconfirmed) | Wegovy pill scripts, International Operations, guidance changes |
| Foundayo type 2 diabetes decision | US submission made; decision date not stated in sources [3] | Label breadth |
| EU decisions on oral pills | Wegovy pill EMA-approved in July; Foundayo EU review ongoing [4] [8] | European launch pace |
| Retatrutide FDA filing | Q1 2027 [1] | Safety database and label strategy |
| Medicare GLP-1 Bridge | Runs through Dec 31, 2027 [10] | Enrollment and uptake data |
| Viking VK2735 update | Not before early 2027 [19] | Efficacy versus incretin peers |
10. Ways to get exposure
Direct answer: choose by how much single-company risk you can tolerate. The approaches below are not recommendations; they illustrate trade-offs.
| Approach | Examples | Upside | Trade-off |
|---|---|---|---|
| Incumbent stocks | LLY, NVO | Direct exposure to category growth | High concentration; price and policy sensitivity |
| Pharma and healthcare ETFs | XLV, IHE, XPH, PPH (all reported to hold Lilly) | Diversified; lower single-name risk | GLP-1 effect diluted; check Novo and supplier weights |
| Challengers | PFE, AMGN, VKTX | Optionality on next-gen drugs | Binary trial risk; late timelines |
| Supply chain | Bachem, PolyPeptide, Stevanato, West, BD, SCHOTT Pharma, Gerresheimer | Indirect exposure with different cycles | Partial GLP-1 exposure; oral-shift risk |
| Telehealth and channel | HIMS and peers | Direct-to-consumer access growth | Regulatory and partner-dependence risk |
ETF holdings change; confirm current weights on the fund provider's site. See our ETF Hub for how to compare funds.
11. Investor checklist
- Valuation: compare current forward earnings multiples with growth, using up-to-date prices; this article deliberately omits stock prices because they go stale quickly.
- Price versus volume: is volume growth outrunning price declines? Check realized price and gross margin each quarter.
- Concentration: what share of revenue comes from one or two GLP-1 brands?
- Oral mix: what share of new prescriptions are pills, and are patients GLP-1 naive?
- Policy exposure: how much revenue depends on Medicare Bridge, TrumpRx or negotiated prices?
- Pipeline timing: which approvals are 2027 or later, and what is priced in?
- Supplier exposure: for component makers, what percentage of revenue is GLP-1 and how much is oral-sensitive?
- Position size: would a failed trial or a policy shock be survivable for your portfolio?
12. Using AI to research GLP-1 stocks
Direct answer: AI assistants are useful for summarizing filings and building comparison tables, but they can be out of date on prices and guidance. Ask for sources, dates and calculations, and verify against the primary filing.
| Assistant | Prompt to try | Best for |
|---|---|---|
| Claude | “Using Lilly's and Novo's latest quarterly releases, build a table of revenue growth, gross margin and guidance, and flag where the two companies report on different bases.” | Long-document comparison and reasoning about accounting differences |
| ChatGPT | “Summarize the last four quarters of prescription data for Wegovy pill and Foundayo and list what would change the trend. Cite dates.” | Trend summaries with browsing enabled |
| Gemini | “Compare Lilly, Novo, Pfizer, Amgen and Viking pipelines by stage and expected readout date, and show which dates are confirmed.” | Multi-source pipeline roll-ups |
| Perplexity | “What are the latest FDA actions on compounded semaglutide and tirzepatide? Give primary-source links only.” | Fast, cited regulatory updates |
Never paste personal financial details into any assistant, and treat outputs as research leads, not advice.
13. FAQ
What is the best way to invest in GLP-1 drugs?
There is no single best route. Direct exposure comes from Eli Lilly and Novo Nordisk; diversified exposure comes from healthcare or pharma ETFs that hold Lilly, such as XLV, IHE, XPH or PPH; indirect exposure comes from suppliers of peptide ingredients, glass, elastomers and devices. Each route trades concentration for diversification, so verify holdings and revenue exposure first.
Is Eli Lilly or Novo Nordisk the better GLP-1 stock?
Neither is a safe default, because the data point in different directions. In Q2 2026 Lilly grew revenue 48% to $23.0 billion and guided to $85-87 billion for the year, while Novo's adjusted sales grew 7% and its guidance implies flat-to-lower adjusted growth. Valuation, price pressure and pipeline timing matter as much as growth, so compare current multiples before deciding.
Will oral GLP-1 pills replace injections?
Early evidence suggests pills are mostly bringing new patients into the category: Lilly's CEO has said almost all Wegovy pill starters were new to GLP-1 medicines. Higher-dose injectables still show larger average weight loss in trials, so pills look complementary for now. The longer-term risks are lower revenue per patient and less demand for injection components.
Are compounded GLP-1s legal?
Compounded semaglutide and tirzepatide are allowed only in narrow circumstances. FDA declared the tirzepatide shortage over in late 2024 and has since sent warning letters to dozens of sellers, including 30 telehealth companies in March 2026. Compounded versions are not FDA-approved. Patients should discuss options with a licensed clinician; investors should treat compounding as a shrinking, regulated and litigation-prone channel.
How does the Medicare GLP-1 Bridge affect Lilly and Novo?
Since July 1, 2026, eligible Medicare Part D enrollees can get covered weight-management GLP-1s for a $50 monthly copay under a bridge program scheduled to run through December 31, 2027. Manufacturers agreed to a Medicare price reported at about $245 per month. That should expand volume but lower net price per patient, so the net effect depends on uptake.
Which companies are in the GLP-1 supply chain?
Commonly cited names include peptide ingredient makers such as Bachem and PolyPeptide, glass and packaging firms such as Stevanato, SCHOTT Pharma and Gerresheimer, elastomer-component maker West Pharmaceutical, and device makers such as BD. GLP-1 exposure varies widely by company and is often only partly disclosed, so check filings. Lilly and Novo also invest heavily in their own capacity.
What GLP-1 drugs are coming next?
Next-wave candidates include Lilly's retatrutide, with an FDA filing planned for Q1 2027, Novo's CagriSema, Pfizer's monthly GLP-1 from Metsera now in Phase 3, Amgen's MariTide, Roche's CT-388 and petrelintide, and Viking's VK2735. Timelines can slip and results across different trials are not directly comparable, so treat each as a probability-weighted scenario.
What are the biggest risks of GLP-1 stocks?
Key risks are price compression as cash prices and government deals push net prices down, policy changes, new competitors, safety or litigation surprises, and concentration: Mounjaro and Zepbound were about 65% of Lilly's Q2 revenue. Oral substitution, compounding and expectations already priced in can also hurt returns. Position sizing and diversification matter more than any single forecast.
14. Sources and change log
- Eli Lilly, Q2 2026 financial results press release (Aug 5, 2026)
- Eli Lilly Q2 2026 earnings call summary (Webull)
- Zacks: LLY Q2 earnings top, GLP-1 drugs fuel growth
- Novo Nordisk, Q2 2026 company announcement (Aug 4, 2026)
- Quartr: Novo Nordisk Q2 2026 earnings summary
- BioPharma Dive: Lilly launches obesity pill Foundayo
- Gotrade: Foundayo debut-week prescriptions (IQVIA)
- Reuters (via ARY News): Lilly launches Foundayo in the UK, Aug 25, 2026
- Reuters (via WDEZ): FDA approves Foundayo; launch and pricing details
- NBC Palm Springs: Medicare GLP-1 Bridge, $50 copay from July 1, 2026
- HMP Global: Medicare to cover GLP-1s for obesity under pharma deal
- Frier Levitt: FDA warning letters and the Hims-Novo Nordisk deal
- Frier Levitt: Hims & Hers compounded Wegovy pill, rise and fall
- GLP1Clinics: FDA warning letters to 30 telehealth companies (Mar 2026)
- Pharmaceutical Manufacturing: Can CDMOs keep up with GLP-1 demand?
- PharmaNow: GLP-1 manufacturing capacity and bottlenecks
- PolicyRisk: GLP-1 drugs supply map
- Fintool: Pfizer goes all in on obesity after Metsera deal
- Zacks via Finviz: Can Viking Therapeutics hold its edge?
- BioSpace: Amgen on MariTide and its Phase 3 program
- Reuters factbox: weight-loss drug developers (via Stockopedia)
- TipRanks: Lilly Q3 2026 earnings date estimate
Explore more: OneDayAdvisor Master Guide | ETF Hub | Stocks Hub | More pharma articles.
This content is for information only and is not financial, investment, tax, legal or medical advice. Investing involves risk, including loss of principal. Past performance does not guarantee future results.
.png)
Comments